Xilin Wu

机构：State Key Laboratory of Analytical Chemistry for Life Science, Nanjing Medical University, Nanjing University · ORCID：0000-0002-2829-6654

发表论文 41 篇 · 总被引 981 次 · h-index 15

代表论文

• AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia (2021 · Blood Cancer Journal · 被引 163)
• A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration (2021 · Cell Reports · 被引 106)
• Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy (2020 · Acta Biomaterialia · 被引 79)
• A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo (2020 · JCI Insight · 被引 63)
• Infection of humanized mice with a novel phlebovirus presented pathogenic features of severe fever with thrombocytopenia syndrome (2021 · PLoS Pathogens · 被引 45)
• Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration (2024 · Nature Communications · 被引 22)